Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.

There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the benefic...

Descripció completa

Dades bibliogràfiques
Autors principals:	Mcshane, H, Pathan, A, Sander, C, Goonetilleke, N, Fletcher, H, Hill, A
Format:	Journal article
Idioma:	English
Publicat:	2005

Ítems similars

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
per: Whelan, K, et al.
Publicat: (2009)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
per: Fletcher, H, et al.
Publicat: (2008)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
per: Kathryn T. Whelan, et al.
Publicat: (2011-01-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
per: Pathan, A, et al.
Publicat: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
per: Pathan, A, et al.
Publicat: (2012)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
per: Mcshane, H
Publicat: (2008)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
per: de Cassan, S, et al.
Publicat: (2010)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
per: Rowland, R, et al.
Publicat: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
per: Brookes, R, et al.
Publicat: (2008)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
per: Harris, SA, et al.
Publicat: (2014)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
per: Owiafe, P, et al.
Publicat: (2012)

Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (vol 17, pg 1066, 2010)
per: de Cassan, S, et al.
Publicat: (2011)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
per: Sander, C, et al.
Publicat: (2005)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
per: Roger H Brookes, et al.
Publicat: (2008-08-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
per: Rowland, R, et al.
Publicat: (2013)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG immunized adults vaccinated with a new tuberculosis vaccine, MVA85A (Clinical and Vaccine Immunology (2010) 17, 7, (1066-1073))
per: De Cassan, S, et al.
Publicat: (2011)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
per: Scriba, T, et al.
Publicat: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
per: Roger H. Brookes, et al.
Publicat: (2011-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
per: Harris, S, et al.
Publicat: (2013)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
per: Griffiths, K, et al.
Publicat: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
per: Griffiths, K, et al.
Publicat: (2011)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
per: Harris, S, et al.
Publicat: (2011)

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
per: Wajja, A, et al.
Publicat: (2024)

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
per: Verreck, F, et al.
Publicat: (2009)

Correction: MVA.85A Boosting of BCG and an Attenuated, Deficient Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques.
per: Frank A. W. Verreck, et al.
Publicat: (2011-01-01)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
per: Pathan, A, et al.
Publicat: (2007)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
per: Sander, C, et al.
Publicat: (2009)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Publicat: (2011-01-01)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
per: Pathan, A, et al.
Publicat: (2007)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
per: Gilbert, S, et al.
Publicat: (2006)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
per: Minhinnick, A, et al.
Publicat: (2016)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
per: McShane, H, et al.
Publicat: (2004)

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
per: Beveridge, N, et al.
Publicat: (2007)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
per: Sheehan, S, et al.
Publicat: (2015)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
per: Ibanga, H, et al.
Publicat: (2006)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
per: Thomas, Z, et al.
Publicat: (2014)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
per: Mcshane, H, et al.
Publicat: (2016)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
per: Satti, I, et al.
Publicat: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
per: Satti, I, et al.
Publicat: (2014)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
per: Kristin L Griffiths, et al.
Publicat: (2011-01-01)